### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Samuel BOGOCH

Serial No.

(Cont. of 08/031,562)

Filed

(Herewith)

For

**RECOGNIN VACCINES** 

Group Art Unit

1648 (Anticipated)

Examiner

Unknown

ASSISTANT COMMISSIONER FOR PATENTS Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.98

SIR:

In conformance with Applicants' duty of disclosure under 37 C.F.R. § 1.56 (a) and § 1.97(b)(1), the references listed on the attached form PTO-1449 are hereby brought to the Examiner's attention.

Since all the references were cited in parent application Serial No. 08/031,562, no copies of the references are required.

It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear in the "references cited" on any patent to issue therefrom.

Respectfully submitted,

KENY<del>ON & KEN</del>YON

Dated: /5 May 2001

Judith L. Toffenetti (Reg. No. 39,048)

1500 K Street N.W. Suite 700

· 4x 2021220 4201

#### Sheet 1 of 2

FORM PTO-1449
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)

Atty Docket No.

: 9425/46702

Serial No. Inventors

: BOGOCH

Filed

: 15 May 2001

Group Art Unit Examiner

: 1648



#### **U.S. PATENT DOCUMENTS**

Examiner <u>Initial</u>	Patent <u>Number</u>	Patent <u>Date</u>	<u>Name</u>	Class/ Filing Subclass Date	
	5,156,841 4,877,611	10/20/92 10/31/89	RAPP CANTRELL	424,88 424/88	
FOREIGN PATENT DOCUMENTS					
Examiner Initial	Document <u>Number</u>	<u>Date</u>	Country	Class/ Translation Subclass Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Examiner Initial					
	1. Jean-Claude Bystryn: <i>Tumor Vaccines</i> ; Cancer and Mestastasis Review 9:81-91, 1990				
		K. Stevensor	n: Update on Tui	mor Vaccines; Int. J. Clin Lab Res	
EXAMINER			[	DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

#### Sheet 2 of 2

# FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

Atty Docket No.

: 9425/46702

Serial No. Inventors

·

: BOGOCH

Filed

: 15 May 2001

Group Art Unit

: 1648

Examiner

ner

#### OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

3.	Bogoch et al.: Tumor Markers: Malignin and Related Recognins Associated with Malignancy Rather Than With Cell Type Neurochemistry and Clinical Neurology, pp. 407-424, Alan R. Liss Inc. 1980
4.	Freda K. Stevenson: <i>Tumor Vaccines</i> , The FASEB Journal, Vol. 5 June 1991, pp. 2250-2257
5.	Jerrold H. Zar: <i>Biostatistical Analysi</i> s, Prentice-Hall, Inc., Englewood Cliffs, NJ, second edition, 1984, p. 278
6.	Bogoch et al.: Elevated Levels of Anti-Malignin Antibody Are Quantitatively Related to Longer Survival in Cancer Patients Prognosis, pp. 739-747, 1984
EXAMINER	DATE CONSIDERED